Sustained adherence to ESC guideline-recommended medications is associated with lower long-term mortality in heart failure and reduced ejection fraction: Insights from the EPICAL2 cohort.
guidelines
heart failure
long-term outcomes
medication
reduced ejection fraction
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
10
03
2020
revised:
19
04
2020
accepted:
27
04
2020
pubmed:
28
5
2020
medline:
13
4
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
The real-life prognostic impact on long-term survival of continuous or discontinuous adherence to ESC guideline-recommended drugs in heart failure with reduced ejection fraction (HFrEF) patients has rarely been investigated. Here, we present the long-term association of longitudinal prescription of guideline-recommended drugs with 3-year all-cause and cardiovascular (CV) mortality in HFrEF patients. We used data from the EPICAL2 cohort study of 624 hospitalized HFrEF patients. Using the sequence analysis, we classified patients into five groups of long-term adherence according to the continuity/discontinuity of their prescription adherence to guidelines over a 3-year follow-up, as follow: 316 (50.6%) patients in the sustained adherence group, 163 (26.1%) in the sustained non-adherence group, 79 (12.6%) in the adherence to non-adherence group, 43 (6.9%) in the non-adherence to adherence group and 23 (3.7%) in the multiple switches group. The associations between all-cause mortality and CV mortality and the adherence groups were determined by Cox and Fine-Gray models, respectively. To account for immortal time bias, we performed a landmark analysis at 24 months. Patients who died, prior to the landmark time, were excluded from this analysis and long-term adherence groups were redefined. After adjustment for confounding factors, as compared to the sustained non-adherence group, the sustained adherence group showed lower all-cause and CV mortality (hazard ratio HR = 0.37 [0.25-0.56] and sub-distribution hazard ratio SHR = 0.33 [0.20-0.56]). Both clinical outcomes were also significantly improved in the adherence to non-adherence group (HR = 0.25 [0.13-0.45] and SHR = 0.20 [0.10-0.41]), the non-adherence to adherence (HR = 0.24 [0.11-0.55] and SHR = 0.11 [0.04-0.30]), and for the multiple switches group (HR = 0.13 [0.07-0.51] and SHR = 0.12 [0.08-0.43]). Results from landmark analysis were comparable to the main results. As in all observational studies, our results may be affected by residual confounding related to unmeasured confounders, although we attempted to adjust for many confounders. Even a discontinuous prescription of the recommended drugs over time was associated with better long-term outcomes. In other words, whatever the time of HFrEF evolution, prescribing recommended drugs at some point was always better than never prescribing.
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
793-803Subventions
Organisme : National Hospital Program of Clinical Research
Organisme : French Ministry of Health
Organisme : RHU Fight-HF
Organisme : French National Research Agency
ID : ANR-15-RHUS-0004
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891-975.
Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1(1):4-25.
Juillière Y, Ferrières J. Nouvelle ère thérapeutique dans l’insuffisance cardiaque à fraction d’éjection réduite : quelle population de patients français cela concerne-t-il? Annales de Cardiologie et d’Angéiologie. 2016;65(4):237-239.
Tuppin P, Cuerq A, de Peretti C, et al. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis. 2013;106(11):570-585.
Tuppin P, Cuerq A, de Peretti C, et al. Two-year outcome of patients after a first hospitalization for heart failure: A national observational study. Arch Cardiovasc Dis. 2014;107(3):158-168.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-2442.
McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-869.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019;393(10175):1034-1044.
Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414-1423.
Poelzl G, Altenberger J, Pacher R, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175(1):83-89.
Frankenstein L, Remppis A, Fluegel A, et al. The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail. 2010;12(6):574-580.
Komajda M, Schöpe J, Wagenpfeil S, et al. Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2019;27(1):921-929.
Gayat E, Arrigo M, Littnerova S, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart Fail. 2018;20(2):345-354.
Busson A, Thilly N, Laborde-Castérot H, et al. Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort studyqualify. Eur J Intern Med. 2018;1(51):53-60.
Laborde-Castérot H, Agrinier N, Zannad F, et al. Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality. Medicine (Baltimore) [Internet]. 2016;95(37):e4399.
Bitar S, Agrinier N, Alla F, Rossignol P, Mebazaa A, Thilly N. Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: results from the EPICAL2 cohort study. Pharmacoepidemiol Drug Saf. 2019;28(11):1489-1500.
Analyzing and Visualizing State Sequences in R with TraMineR | Gabadinho | Journal of Statistical Software. [cited 2018 May 17]; https://www.jstatsoft.org/article/view/v040i04
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499.
Agarwal P, Moshier E, Ru M, et al. Immortal Time Bias in Observational Studies of Time-to-Event Outcomes. Cancer Control [Internet]. 2018;25(1):107327481878935.
Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199.
Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435.
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis: incremental benefit of drug therapies for chronic HFrEF. Eur J Heart Fail. 2018;20(9):1315-1322.
Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215-1218.
Störk S, Hense HW, Zentgraf C, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail. 2008;10(12):1236-1245.
Zannad F, Cardiorenal RP, Revisited S. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929-944.
Lien CTC, Gillespie ND, Struthers AD, McMurdo MET. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail. 2002;4(1):91-98.
Mathes T, Jaschinski T, Pieper D. Adherence influencing factors - a systematic review of systematic reviews. Arch Public Health [Internet]. 2014;72(1).
Daamen MA, Hamers JP, Gorgels AP, Tan FE, Schols JM, Brunner-la Rocca H-P. Treatment of heart failure in nursing home residents. J Geriatr Cardiol. 2016;13(1):44-50.
Kapoor JR, Kapoor R, Ju C, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464-472.
Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019;13:l223.
Rothman KJ. Modern epidemiology [Internet]. Lww; 2012 [cited 2019 Oct 14]. https://www.biblio.com/book/modern-epidemiology-kenneth-j-rothman/d/955031309